Skip to main content

Inovio Pharmaceuticals, Inc.

INO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001055726

No open-market purchases or sales by Inovio Pharmaceuticals, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $36.1M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Inovio Pharmaceuticals, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of INO: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders98105+7
Shares8.57M13.3M+4.78M (+55.8%)
Value$49.5M$24.4M−$25.1M (−50.7%)

New holders (26)

Institutions that held Inovio Pharmaceuticals, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to INO in Q4 2024
InstitutionSharesValue% of portfolio
Stonepine Capital Management, LLC1,050,000$1.92M1.55%
AIGH Capital Management LLC654,115$1.20M0.45%
Highbridge Capital Management LLC300,000$549.0K0.02%
UBS Oconnor LLC225,000$411.8K0.01%
Wolverine Asset Management LLC97,400$178.2K0.00%
Susquehanna Fundamental Investments, LLC65,669$120.2K0.00%
Graham Capital Management, L.P.62,567$114.5K0.00%
XTX Topco Ltd52,230$95.6K0.01%
Prime Capital Investment Advisors, LLC31,290$57.3K0.00%
Boothbay Fund Management, LLC24,000$43.9K0.00%
Bank of Montreal23,495$43.0K0.00%
Citadel Advisors LLC21,728$39.8K0.00%
JustInvest LLC21,112$38.6K0.00%
Alpine Global Management, LLC16,906$30.9K0.01%
Engineers Gate Manager LP13,502$24.7K0.00%
Intech Investment Management LLC12,007$22.0K0.00%
Police & Firemen's Retirement System of New Jersey5,106$9.34K0.00%
SBI Securities Co., Ltd.4,114$7.53K0.00%
Picton Mahoney Asset Management1,923$4.00K0.00%
CWM, LLC1,734$3.00K0.00%
Federated Hermes, Inc.1,613$2.95K0.00%
MAI Capital Management958$1.75K0.00%
Crowley Wealth Management, Inc.404$7390.00%
Wingate Wealth Advisors, Inc.20$370.00%
Golden State Wealth Management, LLC10$180.00%
Wood Tarver Financial Group, LLC24$00.00%

Sold out (19)

Institutions that held Inovio Pharmaceuticals, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.